Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference

Rhea-AI Summary

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) announced its participation in H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13th to 15th, 2021. CEO Louis Brenner will join a pre-recorded fireside chat available on demand starting at 7:00 a.m. ET on September 13th. This discussion will focus on Allena's innovative oral biologic platform and their lead product candidate, reloxaliase, which is in Phase 3 clinical trials for enteric hyperoxaluria. Investors can access the webcast and schedule one-on-one meetings for deeper insights.

NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will virtually participate in H.C. Wainwright’s 23^rd Annual Global Investment Conference, being held September 13^th – 15^th, 2021.

Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will virtually participate in a fireside chat at the conference. The pre-recorded discussion will be available on demand beginning 7:00 a.m. ET on September 13^th. A recording can also be accessed for 90 days at the link below or via the Allena Pharmaceuticals website within the Investors/Events and Presentations section.

Please see details for the session below:

Date:	7:00 a.m. ET
Time:	Monday, September 13th, 2021
Webcast:	https://journey.ct.events/view/f1d0178c-8b66-4f9b-bbb4-f26ad0dc2801

Management will also be available for 1x1 meetings. If you would like to request a meeting, please email meetings@hcwco.com.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program recently initiated.

Investor Contact
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com 

FAQ

What is Allena Pharmaceuticals participating in on September 13th, 2021?

Allena Pharmaceuticals will participate in H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13th to 15th, 2021.

Who will represent Allena Pharmaceuticals at the conference?

CEO Louis Brenner will represent Allena Pharmaceuticals during a fireside chat at the conference.

What time is the fireside chat scheduled for?

The fireside chat is scheduled to be available on demand starting at 7:00 a.m. ET on September 13th, 2021.

What is reloxaliase, the lead product candidate of Allena Pharmaceuticals?

Reloxaliase is an oral enzyme therapeutic currently in Phase 3 trials for treating enteric hyperoxaluria, a metabolic disorder.

How can investors access the conference webcast for Allena Pharmaceuticals?

Investors can access the webcast via the link provided in the press release or through the Allena Pharmaceuticals website.

What additional product is Allena Pharmaceuticals developing?

Allena is also developing ALLN-346 for treating hyperuricemia in patients with gout and chronic kidney disease.